Follow-up patterns and Multidisciplinary Clinical Approaches in Patients with Mucopolysaccharidosis Type IVA in Colombia
Article Sidebar
Main Article Content
Abstract
Background: There is limited data on the follow-up and management of patients with mucopolysaccharidosis IVA (MPS-IVA) undergoing enzyme replacement therapy (ERT) in Colombia.
Objective: We aim to assess the real-world data of patients with MPS-IVA undergoing ERT in Colombia to understand patient profiles, follow-up patterns, and treatment dynamics.
Methods: A convenience sample of geneticists and pediatric neurologists were recruited from November-2020 to January-2021. The physicians responded to a questionnaire-based report for each patient under their care regarding the patient profiles, follow-up patterns, and treatment dynamics.
Results: A total of 24 physicians (geneticists [92%] and pediatric neurologists [8%]) provided data on 107 patients with MPS-IVA. Patients were diagnosed through molecular (36%) and/or enzymatic assays (97%). The mean age of patients was 19.5 years and 51% were male. The average time from first symptom to diagnosis was 7.1 years. The mean age at first symptoms was 4 years and at diagnosis was 11 years, further, the mean age at first ERT was 15 years. There was an increase in assessments after ERT initiation; parameters most frequently evaluated were weight, height, and echocardiography; quality of life, 6MWT, and 3-minute stair-climb test were the least frequent. ERT interruptions >2 months were observed in 63% patients.
Conclusions: Monitoring of MPS-IVA patients receiving ERT remains suboptimal in Colombia. Establishing national management guidelines and implementing centralized reference centers, where patients can receive comprehensive care are warranted for ensuring appropriate systems, services, and support as a priority, with a potential positive effect in the course of the disease.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Creative Commons
License Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
You are free to:
Share - copy and redistribute the material in any medium or format.
Adapt - remix, transform, and build upon the material The licensor cannot revoke these freedoms as long as you follow the license terms.
• Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• NonCommercial — You may not use the material for commercial purposes.
• ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
• No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
References
Morris CP, Guo XH, Apostolou S, Hopwood JJ, Scott HS. Morquio A syndrome: cloning, sequence, and structure of the human N-acetylgalactosamine 6-sulfatase (GALNS) gene. Genomics. 1994;22(3):652-4.DOI: 10.1006/geno.1994.1443.
Tomatsu S, Nishioka T, Montaño AM, Gutierrez MA, Pena OS, Orii KO, et al. Mucopolysaccharidosis IVA: identification of mutations and methylation study in GALNS gene. J Med Genet. 2004;41(7):e98.DOI: 10.1136/jmg.2003.018010.
Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020;9(1):1-9.DOI: 10.5582/irdr.2020.01011.
Gómez A, Robles R, Suárez-Obando F. Estimación de las frecuencias de las mucopolisacaridosis y análisis de agrupamiento espacial en los departamentos de Cundinamarca y Boyacá. Biomédica: revista del Instituto Nacional de Salud. 2012;32.DOI: 10.7705/biomedica.v32i4.574.
Pachajoa H, Acosta MA, Alméciga-Díaz CJ, Ariza Y, Diaz-Ordoñez L, Caicedo-Herrera G, et al. Molecular characterization of mucopolysaccharidosis type IVA patients in the Andean region of Colombia. Am J Med Genet C Semin Med Genet. 2021;187(3):388-95.DOI: 10.1002/ajmg.c.31936.
Peracha H, Sawamoto K, Averill L, Kecskemethy H, Theroux M, Thacker M, et al. Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA. Mol Genet Metab. 2018;125(1-2):18-37.DOI: 10.1016/j.ymgme.2018.05.004.
Lavery C, Hendriksz C. Mortality in patients with morquio syndrome a. JIMD Rep. 2015;15:59-66.DOI: 10.1007/8904_2014_298.
Hendriksz CJ, Harmatz P, Beck M, Jones S, Wood T, Lachman R, et al. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2013;110(1-2):54-64.DOI: 10.1016/j.ymgme.2013.04.002.
Hendriksz CJ, Berger KI, Giugliani R, Harmatz P, Kampmann C, Mackenzie WG, et al. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A. 2015;167a(1):11-25.DOI: 10.1002/ajmg.a.36833.
Suarez-Guerrero JL, Gómez Higuera PJ, Arias Flórez JS, Contreras-García GA. [Mucopolysaccharidosis: clinical features, diagnosis and management]. Rev Chil Pediatr. 2016;87(4):295-304.DOI: 10.1016/j.rchipe.2015.10.004.
Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44(Suppl 2):120.DOI: 10.1186/s13052-018-0562-1.
Mitchell JJ, Burton BK, Bober MB, Campeau PM, Cohen S, Dosenovic S, et al. Findings from the Morquio A Registry Study (MARS) after 6 years: Long-term outcomes of MPS IVA patients treated with elosulfase alfa. Mol Genet Metab. 2022;137(1-2):164-72.DOI: 10.1016/j.ymgme.2022.08.007.
Long B, Tompkins T, Decker C, Jesaitis L, Khan S, Slasor P, et al. Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study. Clin Ther. 2017;39(1):118-29.e3.DOI: 10.1016/j.clinthera.2016.11.017.
Schweighardt B, Tompkins T, Lau K, Jesaitis L, Qi Y, Musson DG, et al. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial. Clin Ther. 2015;37(5):1012-21.e6.DOI: 10.1016/j.clinthera.2014.11.005.
Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14(1):137.DOI: 10.1186/s13023-019-1074-9.
Alvear-Sedan CC, Barboza-Ubarnes, M., y Grijalba-Romero, M. Ángel. Experiencia clínica y bioquímica de las mucopolisacaridosis en Cartagena de Indias, Colombia. Revista Ciencias Biomédicas. 2020;4(1):152–8.DOI: 10.32997/rcb-2013-2765.
Instituto Nacional de Salud. Informe de evento: Enfermedades Huérfanas - Raras. Primer semestre de 2022.
Céspedes Useche LP. Una mirada imageneológica, fisiopatológica y actualizada de las enfermedades huérfanas, desde la perspectiva real del departamento del Tolima. cientific and Educational Medical Journal. 2021;2(1):206-26.DOI: 2745-0252.
Alianza Iberoamericana de Enfermedades Huérfanas (ALIBER), Salazar Ceballos LV, Quiroga Carrillo M, Mesa Correa M, Suárez Obando F. Estudio ENSERio LATAM. Estudio sobre la situación de necesidades socio-sanitarias de las personas con enfermedades raras en latinoamérica. 2023. p. 5-51.
Guerrero R, Prada SI, Pérez AM, Duarte J, Aguirre AF. Universal health coverage assessment Colombia. Global Network for Health Equity. 2015.
Vallejo Alzate N, Hurtado PM. El Síndrome de Morquio en Colombia desde la molécula a la clínica. Pediatría. 2022;54(4):146-54.DOI: 10.14295/rp.v54i4.193.
Solano VM, Mandujano CYC, Avila-Rejon CA, Espin VH, Montaño HPQ. Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries. Mol Genet Metab Rep. 2021;28:100769.DOI: 10.1016/j.ymgmr.2021.100769.
Sawamoto K, Álvarez González JV, Piechnik M, Otero FJ, Couce ML, Suzuki Y, et al. Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management. Int J Mol Sci. 2020;21(4).DOI: 10.3390/ijms21041517.
Moreno Giraldo LJ, Escudero Rodriguez AM, Sanchez Gomez A, Satizabal Soto JM. Clinical and molecular characteristics of colombian patients with mucopolysaccharidosis IVA, and description of a new galns gene mutation. Mol Genet Metab Rep. 2018;16:53-6.DOI: 10.1016/j.ymgmr.2018.06.008.
Moreno Giraldo LJ, Satizábal JM, Sánchez Gómez A. Variantes del Complejo MPS en población Colombiana. Revista de la Asociación Colombiana de Ciencias Biológicas. 2020:124-42.DOI: 10.47499/revistaaccb.v1i32.213.
Romo-Erazo L, Pérez-Restrepo R, Orozco-Hernández JP, Estrada-Álvarez JM, Porras-Hurtado GL. Hallazgos ecocardiográficos de pacientes pediátricos con mucopolisacaridosis tipo IV-A con mutación c.901G>T en el gen GALNS en un centro de salud de cuarto nivel de Colombia en el periodo de 2012-2019. Medicas UIS. 2022;35:19-25.DOI: 10.18273/revmed.v35n3-2022002.
Tapiero-Rodriguez SM, Acosta Guio JC, Porras-Hurtado GL, García N, Solano M, Pachajoa H, et al. Determination of genotypic and clinical characteristics of Colombian patients with mucopolysaccharidosis IVA. Appl Clin Genet. 2018;11:45-57.DOI: 10.2147/tacg.S141881.
Harmatz PR, Lampe C, Parini R, Sharma R, Teles EL, Johnson J, et al. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program. J Inherit Metab Dis. 2019;42(3):519-26.DOI: 10.1002/jimd.12079.
Politei J, Porras-Hurtado GL, Guelbert N, Fainboim A, Horovitz DDG, Satizábal JM. Enzyme replacement therapy interruption in mucopolysaccharidosis type IVA patients and its impact in different clinical outcomes. JIMD Rep. 2021;58(1):104-13.DOI: 10.1002/jmd2.12192.
Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109(1):54-61.DOI: 10.1016/j.ymgme.2013.01.021.
Quijada-Fraile P, Arranz Canales E, Martín-Hernández E, Ballesta-Martínez MJ, Guillén-Navarro E, Pintos-Morell G, et al. Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience. Orphanet J Rare Dis. 2021;16(1):464.DOI: 10.1186/s13023-021-02074-y.
Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9:32.DOI: 10.1186/1750-1172-9-32.
Ministerio de Salud y Protección Social. Guía para la habilitación de centros de referencia de diagnóstico, tratamiento y farmacias para la atención integral de las enfermedades huérfanas y la conformación de la red y subredes de centros de referencia para su atención. In: primaria Ddpdsya, editor. 2018.